LOX and breast adenocarcinoma: Whilst for cholangiocarcinoma (EGI-1) and pancreatic adenocarcinoma models (KPC and mPDAC), LOX inhibition drastically decreases tumor stiffness, this effect is less marked in the breast adenocarcinoma model (MMTV-PyMT).